

MEETING DIRECTORS

| | | | | |
|-------------|--------------|--------------|--------------------------|--------|
| Prof. | Dimitrios | Karnabatidis | MD, PhD, EBIR, FCIRSE | GREECE |
| Asst. Prof. | Konstantinos | Katsanos | MD, MSc, PhD, EBIR | GREECE |
| Asst. Prof. | Panagiotis | Kitrou | MD, MSc, PhD, EBIR | GREECE |

HONORARY MEETING CHAIR

| | | | | |
|-------|-----------|---------|--------------------------|--------|
| Prof. | Dimitrios | Siablis | MD, PhD, EBIR, FCIRSE | GREECE |
|-------|-----------|---------|--------------------------|--------|

FACULTY

| | | | | |
|-------------|------------|------------|------------------|--------|
| Dr. | Jose Maria | Abadal | MD, PhD, EBIR | SPAIN |
| Dr. | Liana | Balta | MD | GREECE |
| Prof. | Prabir Roy | Chaudhury | MD, PhD, FRCP | USA |
| Dr. | Bart | Dolmatch | MD | USA |
| Asst. Prof. | Georgios | Georgiadis | MD, PhD | GREECE |

| | | | | |
|-------------|---------|-------------|----------------------------|--------|
| Dr. | James | Gilbert | MD, PhD, MA Ed, FRCS | UK |
| Prof. | Ziv | Haskal | MD | USA |
| Prof. | Jose | Ibeas | MD, PhD | SPAIN |
| Dr. | Ounalli | Jaffer | MBBS, MRCP, FRCR | UK |
| Asst. Prof. | Stavros | Kakkos | MD, PhD | GREECE |
| Dr. | Narayan | Karunanithy | MD, EBIR | UK |
| Dr. | Elias | Kehagias | MD, PhD | GREECE |
| Dr. | Asim | Khwaja | MD | UAE |
| Asst. Prof. | Po-Jen | Ko | MD, PhD | TAIWAN |

| | | | | |
|-------------|------------|--------------|--|---------|
| Asst. Prof. | Miltiadis | Krokidis | MD, PhD, EBIR, FCIRSE, FRCR, FSIR | GREECE |
| Dr. | Georgios | Lampropoulos | MD, PhD | GREECE |
| Prof. | Jeffrey | Lawson | MD, PhD | USA |
| Prof. | Miltiadis | Lazarides | MD, PhD, FEBVS | GREECE |
| Prof. | Romaric | Loffroy | MD, PhD, EBIR | FRANCE |
| Dr. | Panagiotis | Papadimatos | MD | GREECE |
| Asst. Prof. | Marios | Papasotiriou | MD, PhD | GREECE |
| Dr. | Guido | Saracino | MD | ITALY |
| Prof. | Daniele | Savio | MD | ITALY |
| Asst. Prof. | Guerkan | Sengolge | MD | AUSTRIA |
| Dr. | David | Shemesh | MD | ISRAEL |

| | | | | |
|-------------|-------------|--------------|-----------------------------|-------------|
| Asst. Prof. | Stavros | Spiliopoulos | MD, PhD, EBIR, FCIRSE | GREECE |
| Dr. | Tobias | Steinke | MD | GERMANY |
| Dr. | Jimmy | Tan | MD | TAIWAN |
| Dr. | Michail | Theofanis | MD | GREECE |
| Prof. | Jan | Tordoir | MD, PhD | NETHERLANDS |
| Prof. | Scott | Trerotola | MD | USA |
| Dr. | Mohammad Al | Twalah | MD | KSA |

NETWORK NAME:


WavelinQ

PASSWORD:

evameeting2019



Program in PDF



www.evameeting.org

PROGRAM



ENDO VASCULAR ACCESS

PATRAS / June 2019
INAUGURAL EVENT

IMPORTANT MEETING INFORMATION

EMERGENCY CALL TO: **Nicos Giannikas:**
0030 6988332487
Viber, WhatsApp, WeChat, Cell phone

Periklis Nassopoulos:
0030 6973205800
Viber, WhatsApp, WeChat, Cell phone

EMAIL TO: **secretariat@evameeting.org**

VENUE: **Conference & Cultural Center, University Campus, University of Patras**

WIFI: Network Name: **WavelinQ**
Password: **evameeting2019**

SESSION HOURS: Friday 21st & Saturday 22nd
8:00 – 16:00

BREAKS: Friday 21st & Saturday 22nd
Coffee Break: 11.30-12.00
Lunch Break: 13.30-14.30

LIVE CASES: Friday, June 21st 10.30-11.30
Dec clotting Procedures (K. Katsanos)

Saturday, June 22nd 09.00-10.00
Drug-Coated Devices. (P. Kitrou)
?!

INDUSTRY SESSION: Friday June 21st, 12:45-13:30
BD Symposium: AVF Creation with The WavelinQ Procedure

Saturday June 22nd, 12:45-13:30
BD Symposium: Vascular Access Management Evidence-Based Solutions



| FRIDAY, JUNE 21 ST | | |
|--|---|--------------------------|
| TIME | SESSION | SPEAKER |
| 08.00 – 08.30 ARRIVAL - BADGE COLLECTION | | |
| | | |
| 08.30 – 08.45 | Welcome Message from the Meeting Directors What is the E.V.A. Meeting About? | |
| | | |
| 1 | What is New and Interesting in Dialysis Access? | |
| 08.45 – 09.30 | MODERATORS: D. KARNABATIDIS (GREECE),K. KATSANOS (GREECE) | |
| 08.45 – 08.52 | The Nephrologist's view | P.R CHAUDHURY (USA) |
| 08.53 – 09.00 | The Vascular Surgeon's view | D. SHEMESH (ISRAEL) |
| 09.01 – 09.08 | The Interventional Radiologist's view | P. KITROU (GREECE) |
| 09.09 – 09.16 | Multi-Disciplinary Meeting for Dialysis Access. Is it Really Needed? | Z. HASKAL (USA) |
| 09.17 – 09.30 | Discussion PANEL: J. TORDOIR (NETHERLANDS), M.A. TWALAH (KSA), G. SENGOLGE (AUSTRIA) | |
| | | |
| 2 | Trial Updates | |
| 09.30 – 10.30 | MODERATORS: D. KARNABATIDIS (GREECE), J.M. ABADAL (SPAIN) | |
| 09.30 – 09.37 | Lutonix United States & Canada PAS | SO. TREROTOLA (USA) |
| 09.38 – 09.45 | The PAVE Study | N. KARUNANITHY (UK) |
| 09.46 – 09.53 | The Lutonix Global AV Registry | D. KARNABATIDIS (GREECE) |
| 09.54 – 10.01 | Drug-Coated Balloons for the treatment of Symptomatic Central Venous Stenosis | P. KITROU (GREECE) |
| 10.02 – 10.08 | The AveVA & AVeNEW studies | B. DOLMATCH (USA) |
| 10.09 – 10.16 | Clinical Trial End Points for Vascular Access | P.R CHAUDHURY (USA) |
| 10.16 – 10.30 | Discussion | |
| | | |
| 3 | Dec clotting Procedures | |
| 10.30 – 11.30 | MODERATORS: D. KARNABATIDIS (GREECE), B. DOLMATCH (USA) | |
| 10.30 – 11.00 | LIVE Case from Patras University Hospital | K. KATSANOS (GREECE) |
| 10.59 – 11.06 | What do the Guidelines Suggest? What are the Options? | A. KHWAJA (UAE) |
| 11.07 – 11.14 | From Fundamentals to Tips & Tricks | M.A. TWALAH (KSA) |
| 11.15 – 11.22 | Thrombectomy Devices Have Nothing to Offer | N. KARUNANITHY (UK) |
| 11.23 – 11.30 | Thrombectomy Devices Make the Difference | O. JAFFER (UK) |
| | | |
| 11.30 – 12.00 | COFFEE BREAK | |
| | | |

| FRIDAY, JUNE 21 ST | | |
|-------------------------------|--|--------------------------|
| TIME | SESSION | SPEAKER |
| | | |
| 4 | Dialysis Access Treatment Pathway | |
| 12.00 – 12.45 | MODERATORS: D. KARNABATIDIS (GREECE), G. LAMPROPOULOS (GREECE) | |
| 12.00 – 12.07 | Dialysis Prevalence Across the Globe | L. BALTA (GREECE) |
| 12.08 – 12.15 | What is a nephrologist expecting from Endovascular Treatment? | M. PAPASOTIRIOU (GREECE) |
| 12.16 – 12.23 | How to get started. What Cases to Pick | D. SAVIO (ITALY) |
| 12.24 – 12.31 | Cost Effectiveness | K. KATSANOS (GREECE) |
| 12.31 – 12.45 | Discussion PANEL: B. DOLMATCH (USA), M.LAZARIDES (GREECE), J. IBEAS (SPAIN) | |
| | | |
| 5 | BD Symposium: AVF Creation with The WavelinQ Procedure | |
| 12.45 – 13.30 | MODERATORS: D. KARNABATIDIS (GREECE), P. KITROU (GREECE) | |
| | Patient Selection Criteria | T. STEINKE (GERMANY) |
| | Data Update | O. JAFFER (UK) |
| | Mapping and Case Presentation | P. KITROU (GREECE) |
| | | |
| 13.30 – 14.30 | LUNCH BREAK | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| SATURDAY, JUNE 22 ND | | |
|---------------------------------|---|--------------------------|
| TIME | SESSION | SPEAKER |
| | | |
| 1 | Development in the background | |
| 08.00 – 09.00 | MODERATORS: S. SPILIOPOULOS (GREECE), M. LAZARIDES (GREECE) | |
| 08.00 – 08.10 | Histology and Histopathology of vascular access stenosis | G. SENGOLGE (AUSTRIA) |
| 08.11 – 08.21 | Bio-Engineering | J. LAWSON (USA) |
| 08.22 – 08.32 | Systemic therapy | M. PAPASOTIRIOU (GREECE) |
| 08.33 – 08.45 | How close are we to a tailored therapy for the HD patient? | P.R CHAUDHURY (USA) |
| 08.45 – 09.00 | Discussion | |
| | | |
| 2 | Drug-Coated Devices. Do we finally have a new tool? | |
| 09.00 – 10.00 | MODERATOR: KARNABATIDIS (GREECE) | |
| 09.00 – 09.30 | LIVE Case from Patras University Hospital | P. KITROU (GREECE) |
| 09.31 – 09.38 | Overview of evidence so far | S. SPILIOPOULOS (GREECE) |
| 09.39 – 09.46 | What does the future hold? | K. KATSANOS (GREECE) |
| 09.47 – 10.00 | Discussion | |
| | PANEL: SO. TREROTOLA (USA), T. STEINKE (GERMANY) | |
| | | |
| 3 | Immature Fistulas – Early Cannulation Grafts | |
| 10.00 – 11.45 | MODERATORS: S. KAKKOS (GREECE), J. GILBERT (UK) | |
| 10.00 – 10.07 | Immature AVF. A clinical entity. What leads to | G. SARACINO (ITALY) |
| 10.08 – 10.15 | Maturing an Immature Fistula. How to do it? What is the evidence? | SO. TREROTOLA (USA) |
| 10.16 – 10.23 | Early Cannulation Grafts – What do they offer to HD? | P.J. KO (TAIWAN) |
| 10.24 – 10.31 | Is there an algorithm to success? | J. LAWSON (USA) |
| 10.32 – 10.45 | Discussion | |
| | | |
| 4 | Symptomatic Central Venous Stenosis/ Occlusion: The last frontier | |
| 10.45 – 11.30 | MODERATORS: D. SAVIO (ITALY) T. STEINKE (GERMANY) | |
| 10.45 – 10.52 | HERO Graft – Recorded Case | J. GILBERT (UK) |
| 10.53 – 11.00 | What does Surgical Treatment has to offer? | D. SHEMESH (ISRAEL) |
| 11.01 – 11.08 | Surfacer – Recorded Case | G. SENGOLGE (AUSTRIA) |
| 11.09 – 11.16 | What do the Guidelines suggest? | M. KROKIDIS (GREECE) |
| 11.17 – 11.23 | Endovascular Salvage Procedures for Central Veins. When Enough is Enough? | A. KHWAJA (UAE) |
| 11.23 – 11.30 | Discussion | |
| | | |
| 11.30 – 12.00 | COFFEE BREAK | |
| | | |

SATURDAY, JUNE 22ND

| TIME | SESSION | SPEAKER |
|---|--|-----------------------|
| 7 Treating the juxta-anastomotic stenosis. | | |
| 12.00 – 12.45 | MODERATORS: G. GEORGIADIS (GREECE), K. KATSANOS (GREECE) | |
| 12.00-12.10 | Drug-Coated Balloons | M. THEOFANIS (GREECE) |
| 12.11-12.21 | Covered Stents | B. DOLMATCH (USA) |
| 12.22-12.32 | Plain Old Balloon – Cutting Balloon Angioplasty | J.M. ABADAL (SPAIN) |
| 12.33-12.45 | Discussion | |
| 5 BD Symposium: Vascular Access Management Evidence-Based Solutions | | |
| 12.45 – 13.30 | MODERATORS: D. KARNABATIDIS (GREECE), Z. HASKAL (USA) | |
| | The Lutonix® clinical program for the treatment of dysfunctional vascular access | SO. TREROTOLA (USA) |
| | Covera™ Covered Stent for the Treatment of Fistulas and Grafts | B. DOLMATCH (USA) |
| | Treatment Algorithm | P. KITROU (GREECE) |
| | Presentation of Cases | K. KATSANOS (GREECE) |
| 13.30 – 14.30 LUNCH BREAK | | |
| 5 Percutaneous AVF Creation | | |
| 14.30 – 16.00 | MODERATORS: D. KARNABATIDIS (GREECE), T. STEINKE (GERMANY) | |
| | WavelinQ – Recorded Case | P. KITROU (GREECE) |
| | Ellipsys – Recorded Case | R. LOFFROY (FRANCE) |
| | Candidates: How to pick one | T. STEINKE (GERMANY) |
| | What is the experience so far? | T. STEINKE (GERMANY) |

ENDO

VASCULAR

ACCESS

MEETING PATRAS

